COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02571972
Recruitment Status : Completed
First Posted : October 8, 2015
Results First Posted : December 3, 2019
Last Update Posted : December 3, 2019
J. Arch McNamara Research Fund
Mid Atlantic Retina
Information provided by (Responsible Party):
Jason Hsu, MD, Wills Eye

Brief Summary:
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related macular degeneration.

Condition or disease Intervention/treatment Phase
Wet Macular Degeneration Age-related Macular Degeneration Diabetic Macular Edema Retinal Vein Occlusion Drug: Dorzolamide-timolol Phase 2

Detailed Description:

Intravitreal anti-vascular endothelial growth factor (VEGF) agents, including bevacizumab, ranibizumab, and aflibercept, have become the gold standard treatment for neovascular age-related macular degeneration (AMD). Various treatment modalities using these agents have been proposed, including monthly, pro re nata, and treat-and-extend philosophies. Despite frequent and consistent treatment with anti-VEGF therapy, there is a subset of patients who are incomplete or non-responders and have persistent evidence of exudation on spectral-domain optical coherence tomography (SD-OCT), including subretinal fluid (SRF) and/or intraretinal edema.

While clearance of intravitreal anti-VEGF drugs is not completely understood, some studies have suggested that outflow through the anterior chamber may contribute. We hypothesized that by decreasing aqueous production, outflow may also be reduced which could delay the clearance of intravitreal drugs. As a result, we chose topical dorzolamide-timolol since it is a potent aqueous suppressant and is readily available due to its common use in the treatment of glaucoma. The current study aimed to evaluate the efficacy of topical dorzolamide-timolol on anatomic and visual outcomes in anti-VEGF non-responders with neovascular AMD.

Significance: The results of this study will help delineate whether topical aqueous suppression may be useful as adjuvant therapy in patients receiving chronic intravitreal anti-VEGF injections.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Topical Aqueous Suppressants on Response to Intravitreal Anti-vascular Endothelial Growth Factor Injections in Age-related Macular Degeneration (AMD), Retinal Vein Occlusions (RVO) or Diabetic Macular Edema (DME).
Actual Study Start Date : February 1, 2015
Actual Primary Completion Date : September 30, 2015
Actual Study Completion Date : December 20, 2015

Arm Intervention/treatment
Experimental: Dorzolamide-timolol
  • On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal pharmacologic agent administered at prior visit.
  • Subsequent follow-up visits will be at an identical interval to pre-enrollment visit intervals (4, 5, or 6 week intervals) for the study duration.
  • Each subsequent visit will consist of visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan, and intravitreal injection of same pharmacologic agent as prior visits
  • At study conclusion, mean central macular thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height will be measured over the study period for all patients
Drug: Dorzolamide-timolol
On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
Other Name: Cosopt

Primary Outcome Measures :
  1. Mean Central Subfield Thickness (CST) [ Time Frame: 3 visits (8-12 weeks) ]
    Mean central subfield thickness (CST) on spectral domain optical coherence tomography (SD-OCT) on 1 visit prior to enrollment and all visits subsequent to study enrollment

Secondary Outcome Measures :
  1. Visual Acuity [ Time Frame: 3 visits (8-12 weeks) ]
    LogMAR Visual acuity on enrollment and final visit

  2. Maximum Subretinal Fluid Height [ Time Frame: 3 visits (8-12 weeks) ]
    Measurement based on SD-OCT

  3. Maximum Pigment Epithelial Detachment Height [ Time Frame: 3 visits (8-12 weeks) ]
    Measurement based on SD-OCT

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient of Wills Eye Hospital Retina Service and/or Mid Atlantic Retina.
  2. Volunteer patients age 18 years and older.
  3. Healthy enough to participate in the study.
  4. Willing and able to consent to participation in the study.
  5. Diagnosis of wet age-related macular degeneration
  6. Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during this period
  7. Injection of the same anti-VEGF agent for at least two visits prior to study enrollment
  8. Fixed interval between at least two visits prior to study enrollment

Exclusion Criteria:

  1. History of uveitis
  2. Any ophthalmic surgery within previous 6 months, including cataract extraction.
  3. Any history of vitrectomy
  4. History of any glaucoma drop usage or prior glaucoma surgery
  5. Systemic diuretic or corticosteroid usage
  6. Any contraindication (bradycardia, decompensated heart failure, or reactive
  7. airway disease) for topical use of a beta-blocker
  8. Any history of sulfonamide allergy


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02571972

Layout table for location information
United States, Pennsylvania
Wills Eye Hospital / Mid Atlantic Retina
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Wills Eye
J. Arch McNamara Research Fund
Mid Atlantic Retina
Layout table for investigator information
Principal Investigator: Jason Hsu, MD Wills Eye Hospital, Mid Atlantic Retina
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Jason Hsu, MD, PI, Wills Eye Identifier: NCT02571972    
Other Study ID Numbers: IRB#14-435
First Posted: October 8, 2015    Key Record Dates
Results First Posted: December 3, 2019
Last Update Posted: December 3, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Jason Hsu, MD, Wills Eye:
topical aqueous suppression
neovascular age-related macular degeneration
macular edema
intravitreal injection
anti-vascular endothelial growth factor
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Macular Edema
Retinal Vein Occlusion
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors